Loading...
XBRU
FAGR
Market cap1.91bUSD
Aug 28, Last price  
22.50EUR
Name

Fagron NV

Chart & performance

D1W1MN
XBRU:FAGR chart
P/E
18.13
P/S
1.73
EPS
1.24
Div yield, %
1.56%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
11.36%
Revenues
Net income
CFO
Dividend
May 18, 20260.4 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.
IPO date
Oct 05, 2007
Employees
3,035
Domiciled in
BE
Incorporated in
BE

Valuation

No data to show